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ABSTRACT
Current studies aiming at identifying single immune markers with prognostic value have limitations in the
context of complex antitumor immunity and cancer immune evasion. Here, we show how the integration of
several immune markers inﬂuences the predictions of prognosis of gastric cancer (GC) patients. We analyzed
Tissue Microarray (TMA) by multiplex immunohistochemistry and measured the expression of immune
checkpoint molecule PD-L1 together with antitumor CD8 T cells and immune suppressive FOXP3 Treg cells in a
cohort of GC patients. Unsupervised hierarchical clustering analysis of these markers was used to deﬁne
correlations between CD8 T, FOXP3 Treg and PD-L1 cell densities. We found that FOXP3 and PD-L1 densities
were elevated while CD8 T cells were decreased in tumor tissues compared to their adjacent normal tissues.
However, patient stratiﬁcation based on each one of these markers individually did not show signiﬁcant
prognostic value on patient survival. Conversely, combination of the ratios of CD8/FOXP3 and CD8/PD-L1
enabled the identiﬁcation of patient subgroups with different survival outcomes. As such, high densities of PD-L1
in patients with high CD8/FOXP3 and low CD8/PD-L1 ratios correlated with increased survival. Collectively, this
work demonstrates the need for the integration of several immune markers to obtain more meaningful survival
prognosis and patient stratiﬁcation. In addition, our work provides insights into the complex tumor immune
evasion and immune regulation by the tumor-inﬁltrating effector and suppressor cells, informing on the best use
of immunotherapy options for treating patients.
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Introduction
Gastric cancer (GC) is the most signiﬁcant malignancy in Asian
populations and is associated with signiﬁcant mortality. In spite
of novel insights into the molecular basis of GC, current avail-
able therapies do not signiﬁcantly improve the overall patient
survival (OS). Using disease risk stratiﬁcation based on tumor
size, lymph node or distant metastases (TNM staging) and his-
tological grading is not sufﬁcient for the prognosis of individual
GC patients.1 Additional prognostic biomarkers are urgently
needed. The tumor-inﬁltrating immune cells have been pro-
posed to have prognostic value and are a major component of
assessing the therapeutic outcome of various treatments, espe-
cially immunotherapy.2 As such, T cells play critical roles in the
control of tumor development and nodal metastasis; and their
capacity to produce antitumor cytokines was found to be
decreased in patients with high tumor burden and lymph node
metastasis.3 Such immune dysfunction in the tumor environ-
ment correlates with poorer patient survival.4 We and others
have previously discovered that GC tissues exhibited a reduced
frequency and activity of immune effector cells (largely CD8 T
cells) and increased frequency of regulatory T cells (Treg).5-7
How the activity of these tumor inﬁltrating immune cells relates
to GC development and disease prognosis is however poorly
deﬁned. So far, detailed analysis on immune cell inﬁltration,
tumor immune escape and their correlation with clinical param-
eters are rare, knowing that immunosuppressive mechanisms
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within the tumor microenvironment are associated with the dys-
function of tumor-inﬁltrating lymphocytes (TILs).8
Studies using quantitative immunohistochemistry (IHC)
have shown that tumor-inﬁltrating CD8 T cell number (abun-
dance) is an important prognostic parameter in predicting GC
patient survival,9 suggesting that CD8 T cells might be used as
a single biomarker in GC. Nonetheless, the intratumoral pres-
ence of CD8 T cells does not necessarily mean that they can
exert direct anti-tumor activities. Indeed, the function of intra-
tumoral CD8 T cells is controlled by FOXP3 Treg cells and by
immunosuppressive ligands such as programmed death-ligand
1 (PD-L1).10 As such, FOXP3 Tregs play a critical role in tumor
immune evasion,5 which has been reported in a wide array of
human malignancies including GC.5,6 Accordingly, an increase
of intratumoral FOXP3 Tregs is associated with reduced CD8
T cell tumor inﬁltration and worse outcomes for cancer
patients.11 However, a detailed quantitative understanding of
the dynamic relation between tumor-inﬁltrating CD8 T cells
and those expressing PD-L1, and FOXP3 Tregs, and their
potential as immune and prognostic biomarkers remains to be
clearly established in GC.
In this study, we analyzed three key immune marker expres-
sion including checkpoint molecule PD-L1, antitumor T cell
marker CD8 and immune suppressive Treg marker FOXP3 as
well as their potential prognostic value in GC. More speciﬁcally,
relying on multiplex immunohistochemistry (mIHC) of forma-
lin-ﬁxed parafﬁn-embedded (FFPE) tumor tissue microarrays
(TMAs), we explored the relationship between these markers
in cancer tissues and their adjacent normal tissues derived
from 84 GC patients, and related such data to disease progno-
sis, patient survival and stratiﬁcation. Moreover, our patient
clustering approach was validated using an RNAseq dataset
from a TCGA cohort.
Methods
Sample and tissue microarray preparation
GC tissues were obtained from Shanghai Jiao Tong Univer-
sity, Ruijin Hospital. These tissues were formalin-ﬁxed and
parafﬁn-embedded. All protocols using human specimens
were approved by Shanghai Jiao Tong University Human
Ethics Committee, and informed consent was obtained
from all patients. One TMA included 180 GC tissues from
patients (90 paired tumor and adjacent normal tissues), but
12 samples (6 paired tumor and adjacent normal tissues)
were excluded due to incompleteness of the tissues. Detailed
information is shown in Supplementary Table S1. TMAs
were made based on pathology diagnosis of each tissue. The
blocks were assembled and an independent surgical pathol-
ogist reviewed the H&E slide for each case. The pathologist
then circled the area of the block, localizing a representative
tumor region from which a core was extracted for our
TMAs. Then we applied H&E staining on TMAs to validate
pathology type of each tissue on each TMA, and the results
of H&E staining are shown in Supplementary Fig S1. The
core diameter on each TMA in this study was 1.5 mm,
which was much larger than the normal TMA core
(0.6 mm),12 to provide more representative tissues on TMA.
Immunohistochemistry
GC parafﬁn blocks were processed into four-micrometer-thick
sections and mounted on slides for staining. First, the slides
were deparafﬁnized in xylene using ethanol series (75%, 50%,
25%). Antigen recovery was performed by microwaving the
samples for 15 min in citrate buffer (pH 6.0), and the slides
were cooled for 30 min. Endogenous peroxidases were then
blocked by treating the tissues with 3% H2O2 for 10 min. Then,
the tissues were incubated with blocking serum for 20 min at
room temperature. Afterwards, the slides were incubated over-
night with anti-CD8 (1:500 dilution in SignalStain Antibody
Diluent), anti-PD-L1 (1:250 dilution in SignalStain Antibody
Diluent), and anti-FOXP3 (1:350 dilution in SignalStain Anti-
body Diluent) primary antibodies (Cell Signaling, USA) respec-
tively at 4

C and incubated with horseradish peroxidase (HRP)
(Vectastain ABC kit, USA) for 30 min on the next day. The
slides were incubated with ABC reagent (Vectastain ABC kit,
USA) for another 30 min at room temperature, washed with
TBST, and stained with 3, 30-diaminobenzidine (DAB). Finally,
the slides were counterstained with hematoxylin and mounted
with coverslips in DPX (Sigma, USA) for imaging. All staining
preparations included a non-primary-antibody control, details
are described by previous studies.12,13
Multiplex immunohistochemistry
For mIHC staining, a PD-L1, FOXP3 and CD8a multiplex IHC
antibody panel kit (Cell Signaling, USA) and Opal 4-color ﬂuo-
rescent IHC kit (PerkinElmer, USA) were used.14 First, the con-
centration and the application order of the three antibodies
were optimized, and the spectral library was built based on the
single-stained slides. The slides were ﬁrst deparafﬁnized by
xylene and ethanol (Concentration of 100%, 75%, 50% and
25%) and antigen retrieval was performed by microwave. After
incubating with 3% H2O2 (freshly made) for 10 mins, the tis-
sues were blocked in blocking buffer for another 10 mins at
room temperature. Then the tissues were incubated by primary
antibody (Cell signaling, USA), secondary-HRP (Cell signaling,
USA) and Opal working solution (PerkinElmer, USA). The
slides then were mounted with ProLong Gold Antifade Reagent
with DAPI (Cell signaling, USA).
Evaluation of immunostaining
All the slides were scanned using a Nikon C1 confocal micro-
scope (Nikon, Japan). The Nikon C1 confocal microscope pro-
duces virtual images of full tissue scans which can be analyzed
visually as well as automatically using image processing algo-
rithms. The full tissue sections allow large scale histological
evaluations with high precision across the complete section,
which can avoid the ambiguity caused by variable cell densities
in different parts of the tissues. The positive stained CD8 and
FOXP3 cell numbers per mm2 and the average intensity of PD-
L1 per mm2 were analyzed by ImageJ software (ImageJ 1.51 n,
National institutes of health, USA). All these results were
described as the density (cells per mm2) of positive stained cells
in the following analysis. The detailed protocol is described in
the Supplementary Methods.
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RNA-seq and clinical information data from TCGA
We used publicly available TCGA data in this study, clini-
cal information and mRNA expression data were down-
loaded from the NCI’s Genomic Data Commons (GDC)
portal (https://portal.gdc.cancer.gov). Raw RNA-seq count
matrix and clinical information were obtained using TCGAbio-
links (2.5.7) package in R (3.4.0). The count matrix was trans-
formed into log2 count per million (lcpm) using edgeR (3.18.1)
package. Lcpm values of CD274 (PD-L1), CD8 A (CD8) and
FOXP3 RNA were extracted, and the ratio of CD8 A to CD274
and CD8 A to FOXP3 was calculated by deducting lcpm value
of corresponding genes. TCGA-STAD cohort contained 32
normal and 375 tumor samples. We used the tumor samples to
obtain hierarchical clustering of the patients using two different
combinations of predictors, similar to our TMA data analysis.
The ﬁrst combination relied on the 3 single predictors includ-
ing FOXP3, CD8 and PD-L1. The second combination relied
on the 2 ratios including CD8/FOXP3 and CD8/PD-L1.
Hierarchical clustering analysis
Hierarchical clustering was used to deﬁne subgroups of GC
patients both in TMA and TCGA cohorts. We used densities of
CD8, FOXP3 and intensity of PD-L1 expression along with ratios
of CD8/FOXP3 and CD8/PD-L1 as predictors in the TMA cohort.
The expression and ratios were log2 transformed and Euclidean
distance was calculated to plot the heatmaps. The tumor samples
in the TMA cohort were sub-divided into 3 clusters.
Raw mRNA counts of CD8, FOXP3 and PD-L1 from the
TCGA cohort were used to calculate the ratios of CD8/FOXP3
and CD8/PD-L1. The mRNA counts and their ratios were also
log2 transformed (e.g lcpm), and Euclidean distance was calcu-
lated to plot the heatmaps. The expression was indicated from
red (high level) to blue (low level). Heatmaps and hierarchical
clusters were generated in Rstudio (Version 3.2.0), as described
in our previous studies.13,15 The tumor samples in the TCGA
cohort were sub-divided to mirror those from the TMA cohort.
We found k D 5 gave best representation of the three clusters
corresponding to TMA cohort.
Kaplan–Meier survival curve
The Kaplan–Meier survival curve and p values were gener-
ated using survminer (0.4.0) package. In each cluster, we
divided the samples into two subgroups by the median
value of expression or ratio. The samples in each cluster
were ﬁtted to the Cox proportional hazard model to test if
it violates the assumption. In case where the proportional
hazard model agreed, Log rank test was used to calculate p
value. Otherwise, we used Fleming-Harrington test (p D 1,
q D 1) to adjust the p value.
Statistical analyses
Statistical analyses were carried out using the Kruskal-Wallis
test for nonparametric analysis in GraphPad Prism (Version
5.0), and differences were considered statistically signiﬁcant at
p < 0.05.
Results
Differential expressions pattern of CD8, FOXP3
and PD-L1 in GC
We have developed a novel multiplex immunolabelling
protocol with a Tyramide Signal Ampliﬁcation (TSA) signaling,
using Opal ﬂuorophores (Supplementary Table S2), which
allows for the simultaneous evaluation of 4 markers in a single
tissue section. We assessed the concurrent densities of CD8 T
cells, FOXP3 Treg cells and PD-L1 cells in tumor tissues and
adjacent normal tissues, relying on a 4-color mIHC staining of
the TMA samples (Fig. 1 A–D). The PD-L1 was detected in the
cell membrane and cytoplasm and was visible in tumor,
stromal, and immune cells, but not in non-neoplastic gastric
epithelium (Supplementary Fig S2). We also compared tumor
tissues (Fig. 1E) to adjacent normal tissues from the same
patient (Fig. 1 F). Two predominant patterns of immune inﬁl-
tration were observed in our cohort: tumors with extensive
immune inﬁltration showed high PD-L1 and FOXP3
densities of staining (Fig. 1G); and those with limited immune
inﬁltrates were associated with low PD-L1 and FOXP3 positive
cells (Fig. 1 H).
Decreased CD8 /FOXP3 and CD8 /PD-L1 cell densities
ratios were detected in GC tumors
We initially compared the densities of CD8 T cells, FOXP3
Treg cells and PD-L1 cells between the GC tissues and paired
adjacent normal tissues. We found an increase in densities of
FOXP3 and PD-L1 in tumor tissues (p < 0.01) (Fig. 2A, B).
This contrasted with the signiﬁcantly decreased densities of
CD8 in these tumor tissues (p < 0.01) (Fig. 2 C). Next, we eval-
uated the ratios of CD8 to FOXP3 densities. Adjacent normal
tissues exhibited a signiﬁcantly higher CD8/FOXP3 ratio com-
pared with that in the GC tissues (Fig. 2D). Similarly, although
not statistically signiﬁcant, CD8 /PD-L1 ratios were often
increased in adjacent normal tissues compared with those in
GC tissues (Fig. 2E). These results collectively indicated the
immunosuppressive roles of FOXP3 Treg cells and PD-L1
expressed cells, likely expressed on tumor cells and other
tumor-inﬁltrating immune cells in tumor microenvironment.
The relation of CD8 T, FOXP3 Treg and PD-L1 expressed
cells in GC
PD-L1 expressed cells suppress T cell function and induce local
immune suppression, and they are often associated with poorer
prognosis and poorer patient survival in many cancers includ-
ing GC.16 We therefore set out to determine whether there is
any relation between PD-L1, CD8 and FOXP3 expressing cells
patterns (or densities of positive cells per mm2 or intensity of
per mm2). We ﬁrst divided the GC samples into two groups
according to PD-L1 expressing cell densities (PD-L1 expression
high and low) based on the median of PD-L1 expression. We
next compared the densities of CD8, FOXP3 and the ratio of
CD8/FOXP3 cells between the two groups. The density of
CD8 T cells and FOXP3 Treg cells were signiﬁcantly higher in
PD-L1 high expression group (Fig. 3A, B). As shown in
Fig. 3C, there was signiﬁcant positive correlation between the
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density of CD8 cells and FOXP3 Treg cells in GC tissues (r D
0.594, p < 0.01). Moreover, the density of FOXP3 Treg cells
and CD8T cells were also positively correlated with the PD-L1
expression (r D 0.386, p < 0.01, and r D 0.473, p < 0.01,
respectively) (Fig. 3D, E), suggesting that PD-L1 expressed cells
may play their role on impacting both tumor-reactive and
immune suppressive cell populations.
Individual use of CD8, FOXP3 and PD-L1 does not have
prognostic value in GC
We next studied whether using the density levels of CD8 T
cells, FOXP3 Treg cells and PD-L1 expressed cells could help
reﬁne subgroups of GC patients. Heatmap and clustering anal-
yses were performed to assess the potential correlation between
different gastric tumor and adjacent normal tissues. Hierarchi-
cal clustering analyses using densities of CD8, FOXP3 and
intensity of PD-L1 expression were applied to generate several
subgroups of patients. However, we were unable to distinguish
immune signature subgroups between tumor and adjacent nor-
mal groups with individual predictor of CD8 T cells, FOXP3
Treg cells and PD-L1 cells for such clustering analyses
(Fig. 4A). In line with this, Kaplan-Meier analyses carried out
on the entire patient cohort showed that the individual parame-
ter of CD8T, FOXP3 Treg cells and PD-L1 expressed cells did
not have signiﬁcant prognostic value on patients’ survival
(Fig. 4 B, C, D).
CD8/FOXP3 and CD8/PD-L1 ratios signature separates GC
samples between tumor and adjacent normal tissue
groups
In contrast to the above-mentioned results, we were able to seg-
regate the samples into two groups correlating with their origin
Figure 1. 4-color mIHC staining images of different GC tissues. A. Representative 4-color mIHC staining of GC tissue is shown. B. PD-L1 expressed cells were visualized
using the FITC channel (green). C. CD8 T cells were visualized using the Cy5 channel (red). D. FOXP3 Treg cells were visualized using the Cy3 channel (yellow). E. Represen-
tative image of GC tumor tissue. F. Representative image of GC adjacent normal tissue (E and F sample from the same patient). G. Representative image of GC tissue with
abundant CD8 T, FOXP3 Treg and PD-L1 expressed cell inﬁltration. H. Representative image of GC tissue with minimum CD 8 T, FOXP3 Treg and PD-L1 expressed cell inﬁl-
tration. DAPI was used to visualize nuclei (blue).
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(tumor or adjacent normal tissues), when CD8/FOXP3 and
CD8/PD-L1 cell densities ratio were used to perform hierarchi-
cal clustering of the samples (Fig. 4E). One group contained
most of the GC tissues and mainly displayed low CD8/FOXP3
and CD8/PD-L1 cell ratios, as shown in Fig. 4E. The other
group, associated with adjacent normal tissues, exhibited rela-
tively high ratios of CD8/FOXP3 and CD8/PD-L1. Next, tumor
tissues were further stratiﬁed into three subgroups according to
their ratios of CD8/FOXP3 and CD8/PD-L1 (Fig. 4F). How-
ever, Kaplan-Meier analyses showed that separation of GC
Figure 3. Independent analysis and correlation of CD8T, FOXP3 Treg and PD-L1 cells in GC tissues. A-B. Signiﬁcantly different densities of CD8T and FOXP3 Treg cell were
detected in GC tissues of PD-L1 low or high densities group (p < 0.05). C-E. Scatter plots of signiﬁcant correlations, Data are represented in a scattered plot for densities
of CD8 and FOXP3, FOXP3 and PD-L1, CD8 and PD-L1 with the best ﬁt line shown (n D 84 for tumor tissues). Correlation coefﬁcient (r-value) and p-value of Pearson’s cor-
relation test is given on top of each panel. Error bars represent SEM.
Figure 2. Comparison of densities in CD8T, FOXP3 Treg, and PD-L1 cell, CD8/FOXP3 and CD8/PD-L1 expression ratios in tumor and adjacent normal tissues. A. The densi-
ties of FOXP3 Treg cells was signiﬁcantly increased in tumor samples compared to adjacent normal samples (p < 0.001). B. The expression of PD-L1 was signiﬁcantly
increased in tumor tissues compared to adjacent normal tissues (p < 0.05). C. The levels of CD8T cells (densities) were signiﬁcantly reduced in tumor areas compared to
adjacent normal tissues (p < 0.01). D. The CD8/FOXP3 ratio was signiﬁcantly decreased in tumor tissues compared to adjacent normal tissues (p < 0.01). E. CD8/PD-L1
ratio in tumor and adjacent normal tissues was found not signiﬁcantly different. Error bars represent SEM.
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patients on the basis of these three subgroups did not allow for
survival prediction (Fig. 4G, middle of right panel).
PD-L1 is a prognostic marker of survival in patients with
high CD8/FOXP3 and low CD8/PD-L1 ratios
In a previous study of GC patients, high levels of PD-L1 in
tumors were found to be negatively correlated with patient
prognosis.17 However, our multivariate analyses failed to ﬁnd
signiﬁcant survival differences based on PD-L1 expressing cells
alone (Fig. 4D). We next tested the hypothesis that differences
may be observed using subgroups of patients. Accordingly, we
analyzed three sub-groups stratiﬁed according to the ratios of
CD8/PD-L1and CD8/FOXP3 in tumors samples (based on
Fig. 4F), and evaluated the prognostic differences of PD-L1
expressed cells in these groups. High expression of PD-L1 was a
signiﬁcant prognostic factor in the Cluster 1 (exhibiting high
ratio of CD8/FOXP3 and low ratio of CD8/PD-L1) (Fig. 5A).
However, in the other two groups (Cluster 2: low CD8/FOXP3
ratio and low CD8/PD-L1 ratio; Cluster 3: high CD8/FOXP3
and high CD8/PD-L1 ratios) PD-L1 1evels did not show prog-
nostic value (Fig. 5B, C). In addition, CD8 levels did not show
prognostic value in any of the subgroups studied (Fig. 5D, E, F).
The prognostic value of PD-L1 levels in patients with high
CD8/FOXP3 and low CD8/PD-L1 ratio might indicate blunted
immune surveillance in these patients.
Low CD8/FOXP3 and high CD8/PD-L1 ratios also correlate
with better survival outcomes
The effect of PD-L1 on CD8T-cell function through FOXP3
cells remains to be clariﬁed, but our study indicated that there
were no signiﬁcant correlations between tumor inﬁltrating
CD8T lymphocytes and the patients’ survival rates (Fig. 4B).
The prognostic value of tumor inﬁltrating CD8T cells for can-
cer is controversial. High levels of tumor inﬁltrating CD8T are
thought to be a good predictor of patient survival for a diverse
set of human cancers, including gastric and ovarian cancer.18,19
However, when evaluating the prognostic value of CD8/FOXP3
ratios in the three subgroups of patients described above (i.e.
Cluster 1: high CD8/FOXP3 and low CD8/PD-L1; Cluster 2:
low CD8/FOXP3 and low CD8/PD-L1; and Cluster 3: high
CD8/FOXP3 and high CD8/PD-L1) (Fig. 5G–L), low ratios
CD8/FOXP3 were found to be predictive of increased survival
in patients from Cluster 3 (Fig. 5I), but not in the other sub-
groups (Fig. 5G, H). Conversely, CD8/PD-L1 ratios did not
Figure 4. Quantitation of densities in CD8, FOXP3 and PD-L1 cells enables patient stratiﬁcation with prognostic value. A. Heatmap representation of hierarchical clustering
of CD8, FOXP3 and PD-L1 density levels is shown, along with a dendrogram of unsupervised hierarchical clustering, for tumor and adjacent normal samples. B-D. Kaplan-
Meier curves illustrating the prognostic effect on overall survival (OS) of expression of CD8, FOXP3 and PD-L1 levels of densities for each marker in the cohort of 84 GC
patients. A median cutoff was used to separate high and low populations. Log rank test was used to determine signiﬁcance. CD8/PDL1 and CD8/FOXP3 based subgroup-
ing enables patient stratiﬁcation with prognostic value. E. Hierarchical clustering of CD8/FOXP3 and CD8/PD-L1 ratios in tumor and adjacent normal samples. F. Hierarchi-
cal clustering of CD8/FOXP3 and CD8/PD-L1 in tumor samples only. G. Kaplan-Meier curves illustrating the prognostic effect on overall survival (OS) of three clusters of
patients generated according to CD8/PDL1 and CD8/FOXP3 ratios of checkpoint markers, based on Fig. 4F.
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have prognostic value in any of the subgroups of patients
(Fig. 5J, K, L). The results demonstrated that CD8 levels can
have prognostic value when used relative to FOXP3 levels in
subgroups of GC patients. CD8/FOXP3 low and CD8/PD-L1
high signatures may reﬂecting a balance between tumor-reac-
tive and immunosuppressive TIL subpopulations.
Validation of clustering signature using RNAseq data from
TCGA cohort
To validate the survival prediction value of our patient cluster-
ing signature analysis in GC, we next analyzed RNA sequencing
of GC samples from TCGA datasets (n D 375 samples). We
tried two different combinations of these ﬁve predictors in the
TCGA cohort, similar to what we did with the TMA data analy-
sis. One combination used the 3 individual predictors including
FOXP3, CD8 and PD-L1 (data not shown). The other combi-
nation used the 2 ratios including CD8/FOXP3 and CD8/PD-
L1. We were unable to identify different immune signature
subgroups, when solely relying on 3 individual predictors.
Therefore, hierarchical clustering analyses relying on the ratio
of CD8/FOXP3 and CD8/PD-L1 was applied to deﬁne the
potential subgroups of patients from the TCGA cohort. As
shown in Fig 6A, we were able to identify ﬁve groups of tumor
tissues stratiﬁed according to their ratios of CD8/PD-L1 and
CD8/FOXP3. Interestingly, three main groups (Cluster 1: low
Figure 5. Kaplan-Meier analyses of overall survival (OS) for CD8/FOXP3 and CD8/PD-L1 in subgroups of patients based on CD8 or PD-L1 levels. A-C. Survival outcomes of
the 84 GC with different expression of PD-L1 from 3 clusters generated according to their CD8/FOXP3 and CD8/PD-L1 ratios. Patients with higher PD-L1 expressions in
Cluster 1 had signiﬁcantly better survival (p < 0.05). D-F. Survival outcomes of the 84 GC with different expression of CD8 in the 3 clusters. Kaplan-Meier analyses of over-
all survival (OS) for CD8/FOXP3 and CD8/PD-L1 in subgroups of patients. G-I. Survival outcomes of the 84 GC patients with different expression of CD8/FOXP3 in the 3 clus-
ters. Patients with lower CD8/FOXP3 levels in Cluster 3 had signiﬁcantly better survival (p< 0.05). J-L. Survival outcomes of the 84 GC patients with different expression of
CD8/PD-L1 in the 3 clusters. A-L. A median cutoff was used to separate high and low densities. Statistical analyses were generated using Log rank test.
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CD8/FOXP3 ratio and low CD8/PD-L1 ratio, Cluster 4: high
CD8/FOXP3 ratio and low CD8/PD-L1 ratio; and Cluster 5:
high CD8/FOXP3 ratio and high CD8/PD-L1 ratio), exhibited
a similar pattern to those observed in our mIHC TMA data
(Fig. 4F). Critically, high expression of PD-L1 was associated
with increased survival prognosis in patients from the Cluster 4
(exhibiting high CD8/FOXP3 ratio and low CD8/PD-L1 ratio)
(Fig. 6E). This result was surprisingly consistent with the result
from our mIHC TMA data. Nonetheless, PD-L1 levels did not
show prognostic value in the remaining four patient subgroups
(Fig. 6B, C, D, F). A summary table (Table 1) details the expres-
sion of these markers in tumor and adjacent normal tissues
along with providing immune patterns in tumor tissues that
related with patients’ prognosis.
Discussion
We have established a novel 4-color mIHC method that facili-
tates concurrent study of multiple parameters in gastric tissues,
with the potential to illuminate our understanding of immune
regulation within tumor microenvironment.20 This technology
may help overcome the current limitations of conventional sin-
gle-color immunohistochemistry approaches used to classify
patients, for instance based on either CD3C or CD8C T cell
inﬁltration.21 In support of this, our study revealed that the
concurrent analysis of several immune cell populations can
serve as a better survival predictor compared with CD8T cell
alone. Critically, integration of data collected from our mIHC
TMA cohort and TCGA cohort with unsupervised hierarchical
clustering, allowed us to deﬁne the correlation expression pat-
terns or density levels of CD8 T cells, FOXP3 Treg cells and
PD-L1 levels in GC tumors.
We found that density levels of inﬁltrating FOXP3 Treg cells
and PD-L1 expression were elevated in GC tissues, while CD8
cell populations were decreased. Nonetheless, the use of these
immune markers, individually considered, failed to show any
prognostic value in GC. We observed that the ratios of CD8/
FOXP3 and, to a less extent, those of CD8 /PD-L1 ratios were
suppressed in tumor tissues. This led us to stratify our cohort
of cancer patients into three groups according to their ratios of
CD8/PD-L1 and CD8/FOXP3, and evaluate the prognostic
value of PD-L1 expression in these subgroups. In these analy-
ses, high levels of PD-L1 were associated with increased sur-
vival in patients with high ratios of CD8/FOXP3 and low ratios
of CD8/PD-L1. Critically, this observation was reproduced in
an independent cohort of patients from TCGA database. Con-
versely, patients with high CD8/FOXP3 and high CD8/PD-L1
ratios had poorer prognosis in our cohort of GC patients. These
ﬁndings may be important to understand the success or failure
of immunotherapies, and develop predictive biomarkers for the
selection of patients with the highest likelihood of response to
treatment.
Through the application of biomarker discovery and valida-
tion, CD8T cell inﬁltrates have been shown to have prognostic
value in various types of cancers. High levels of CD8 and PD-
L1 staining correlate with responses to anti-PD-L1 immuno-
therapy agents in renal cell carcinoma (RCC), melanoma and
Figure 6. Kaplan-Meier analyses of overall survival (OS) for CD8/FOXP3 and CD8/PD-L1 in subgroups of patients from TCGA data. A. Hierarchical clustering of CD8/FOXP3
and CD8/PD-L1 of GC patients (n D 375) from TCGA data. B-F Survival outcomes of the GC patients with different expression of PD-L1 in the 5 clusters generated accord-
ing to their CD8/FOXP3 and CD8/PD-L1 ratios. Patients with higher PD-L1 expressions in Cluster 4 had signiﬁcantly increased survival (p < 0.05). Statistical analyses in
Fig. 6E were generated using Fleming-Harrington test (p D 1, q D 1) and other survival curves were analyzed using Log rank test.
Table 1. Expression of FOXP3, PD-L1, CD8 and their ratios in adjacent normal and
tumor tissues and the relationship with patients’ prognosis.
Markers Adjacent normal tissues Tumor tissues
FOXP3C Low High
PD-L1 Low High
CD8C High Low
CD8/FOXP3 High Low
CD8/PD-L1 No signiﬁcant difference
Tissues Better prognosis Poor prognosis
Tumor tissues High PD-L1 expression
with low CD8/PD-L1
and high CD8/FOXP3
Low PD-L1 expression
with low CD8/PD-L1
and high CD8/FOXP3
Tumor tissues High CD8/PD-L1 and low
CD8/FOXP3
Low CD8/PD-L1 and low
CD8/FOXP3
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non-small cell lung cancer (NSCLC).22 However, patients with
high levels of T cell inﬁltrates together with high intratumoral
PD-L1 expression can also fail to respond to anti-PD-L1 ther-
apy.23 Indeed, complex tumor microenvironments are difﬁcult
to encapsulate with single markers such as CD8 and PD-L1.24
Thus, the use of multiparametric analyses of immune cell types
and checkpoints, such as CD8 T cells, FOXP3 Treg cells and
PD-L1, may provide a more comprehensive picture of immune
phenotypes within the tumor microenvironment, which may
help stratify patients with the best chance of response to
immunotherapies.
Immune response against the tumor is dependent on the
proximity of lymphocytes to the tumor. The presence of
tumor-inﬁltrating CD8T cells has previously been described in
patients with advanced GC.25 Such tumor-inﬁltrating CD8T
cells can recognize and kill speciﬁc tumor-derived cells.
However, in late-stage GC tumor regression, tumor-inﬁltrating
lymphocytes (TILs) are rarely seen in the tumor microenviron-
ment, suggesting that such TILs are more common in early-
stage disease, and that advanced gastrointestinal malignancies
are less immunogenic, presumably due to selection pressure
operating during disease progression.26 Multiple studies have
shown that increased PD-L1 expression correlates with worse
prognosis, highlighting the prognostic value of PD-L1 expres-
sion in GCs.18 As such, elevated expression of PD-L1 is associ-
ated with advanced cancer stage increased nodal metastases
and worse survival outcomes.19 However, our data establish the
need to incorporate the analysis of CD8 and FOXP3 levels to
realize the full prognostic potential of PD-L1 in GC. Our data
show that a subgroup of patients with high expression of PD-
L1 together with high ratios of CD8/FOXP3 and low ratios of
CD8/PD-L1, had increased survival. This suggests that PD-L1
may have augmented anti-tumorigenic activity in select gastric
carcinoma patients through the modulation of speciﬁc immune
interactions between CD8 and FOXP3 cells. Further studies
may help deﬁne the mechanisms underlying these anti-tumori-
genic actions of PD-L1.
The original aim of this study was to deﬁne whether the
tumor microenvironment could be characterized through the
concurrent analysis of three markers on four-micrometer-thick
gastric disease tissue sections.27 We found that the overall
approach was technically reproducible and accurate. In addi-
tion to PD-L1, we also analyzed cell densities levels of CD8 and
FOXP3 populations to measure the balance between anti-
tumor lymphocytes and immunoregulatory/suppressive lym-
phocytes. This relied on the previous demonstration that high
ratios of CD8/FOXP3 cells could be associated with favorable
anti-tumor responses in a variety of solid tumors.28,29 In addi-
tion to determining ratios of CD8/FOXP3, we also analyzed
ratios of CD8/PD-L1 that reﬂect an escape of adaptive immune
responses (i.e. where the antitumoral activity of pre-existing
CD8 T cells located at the tumor margin is suppressed by PD-
L1), and may help predict response to therapy.2 In our study,
the ratios of CD8/FOXP3 and CD8 /PD-L1 were suppressed in
tumor tissues. Using the CD8/PD-L1 ratio, we were able to
classify the samples into three groups. Further integration of
the CD8/FOXP3 ratio increased the complexity of the immune
phenotypes, allowing us to deﬁne more subgroups of patients
with different disease-risk (Fig. 4 F). This approach could be
replicated to deﬁne subgroups of GC patients in samples from
a TCGA cohort (Fig. 6). Elevated tumor PD-L1 expression cor-
related with PD-1 inhibitor response rates in a recent phase I
clinical trial (KEYNOTE-012/ anti-PD-1 monoclonal antibody
pembrolizumab) in patients with advanced PD-L1 positive GC,
which supported a trend towards improved overall response
rate (ORR) and progression-free survival (PFS).30 However, a
few patients with lower responses to the PD-1 inhibitor treat-
ment also had high levels PD-L1 expression.23 We propose that
our approach using concurrent CD8/FOXP3 and CD8/PD-L1
ratios to stratify patients into different risk subgroups may be
useful for predicting the outcome of PD-1 inhibitor therapies
in GC patients.
Our analyses also suggest that high CD8/FOXP3 ratios have
favorable clinical outcomes, in line with several studies demon-
strating an important role for CD8CFOXP3C Treg cells in
tumor immune evasion.31 Critically, high CD8/FOXP3 ratios
together with high PD-L1 levels was associated with better sur-
vival in our GC patients. This ﬁnding is in agreement with a
recent report that high levels of Tregs, denoted by the ratio of
FOXP3/CD3 T-cells, was signiﬁcantly associated with higher
PD-L1 expression in metastatic lesions from renal carcinoma.32
Additionally, we noticed that low ratios of CD8/FOXP3 were
found to be predictive of increased survival in patients from
selected clusters (Cluster 3, Fig. 5I). This signature is indicative
of an escape of adaptive immune responses, and resulting in
blunted immune surveillance.
In conclusion, we show that 4-color mIHC can be used to
better deﬁne immune phenotypes in human GC. Our subgroup
analyses indicate that the ratios of cytotoxic T cells to regula-
tory T cells (CD8/FOXP3) and cytotoxic T cells to PD-L1
(CD8/PD-L1) can predict anti-tumor interactions in the micro-
environment. This suggests that the combined measure of
CD8T cells, FOXP3 Treg cells and PD-L1 levels has more pre-
dictive potential than PD-L1 expression or CD8 levels alone.
These ﬁndings may be important in understanding the mecha-
nisms of immune evasion by the tumor, and the balance
between cells with antitumoral activities and cells with
simmune suppressive activities. Our approach may also provide
more accurate prognosis and help identify GC patients in
which PD-L1 blockade therapy may be more effective.
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